Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDE8B | O95263 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781434 | 1.00 | HSD17B10 (0.46) | HSD17B10PDE8BKDM1ASMN1; SMN2ATM | |
| SCHEMBL1255187 | 1.00 | HSD17B10 (0.46) | HSD17B10PDE8BKDM1ASMN1; SMN2ATM | |
| SCHEMBL5192786 | 0.98 | PDE8B (0.45) | HSD17B10PDE8BKDM1ASMN1; SMN2ATM | |
| SCHEMBL17395340 | 0.98 | PDE8B (0.45) | HSD17B10PDE8BKDM1ASMN1; SMN2ATM | |
| SCHEMBL894504 | 0.95 | HSD17B10 (0.50) | HSD17B10PDE8BSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL115846 | 0.95 | HSD17B10 (0.50) | HSD17B10PDE8BSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL144831 | 0.95 | HSD17B10 (0.50) | HSD17B10PDE8BSMN1; SMN2ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL25198974 | 0.94 | HSD17B10 (0.49) | HSD17B10PDE8BSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL2462455 | 0.89 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2ATMHPGD | |
| SCHEMBL2462453 | 0.89 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2ATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-4423078-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118139858-A | Pyrazin-3 (2H) -one derivatives | 吉利德科学公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117736182-A | MetTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117659023-A | Pyridine acetamide derivative, pharmaceutical composition containing same and medical application of pyridine acetamide derivative | 苏州阿尔脉生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20080318944-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2008-12-25 | — | — | US | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1705179-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2006-09-27 | — | — | EP | disclosed |
| EP-1399441-B1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2006-07-05 | — | — | EP | disclosed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-1399441-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002561-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | HSD17B10 969/4885PDE8B 3322/4885KDM1A 989/4885 |
| US-20080318944-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HSD17B10 2098/4885PDE8B 1738/4885KDM1A 1649/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | HSD17B10 224/4885PDE8B 2120/4885KDM1A 1980/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | HSD17B10 2713/4885PDE8B 3915/4885KDM1A 1846/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | HSD17B10 2713/4885PDE8B 3915/4885KDM1A 1846/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | HSD17B10 1649/4885PDE8B 87/4885KDM1A 2449/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | HSD17B10 4334/4885PDE8B 448/4885KDM1A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.